Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

(There are other medicines registered for obesity treatment in South Africa, but they do not fall into the GLP-1 agonist class. These medicines include orlistat, phentermine and topiramate, and ...

While health insurers widely cover this class of glucagon-like peptide 1 ... than 125,000 adults who began taking the GLP-1 drugs liraglutide, semaglutide, or tirzepatide between January 2018 ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...